Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

161. [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V]

[Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V] Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17 [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17 [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according (...) (type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 554. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Humans; Metformin; saxagliptin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8

Health Technology Assessment (HTA) Database.2018

162. Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes

Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes

Health Technology Wales2018

163. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials

Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials 29205774 2018 01 09 1463-1326 2017 Dec 05 Diabetes, obesity & metabolism Diabetes Obes Metab Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. 10.1111/dom.13185 To assess the evidence supporting the choice of third-line (...) agents in adults with inadequately controlled type 2 diabetes. We searched randomized controlled trials (RCTs) published between January 2000 and July 2017 that reported data on cardiometabolic outcomes and hypoglycaemia for glucose-lowering agents added to metformin-based dual treatments. Data were stratified by background therapy and RCT duration, and synthesized, when possible, with network meta-analyses. A total of 43 RCTs (16 590 participants) were included, with metformin combined

EvidenceUpdates2018

164. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial 29266675 2018 02 07 1463-1326 2017 Dec 21 Diabetes, obesity & metabolism Diabetes Obes Metab Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. 10.1111/dom (...) .13194 To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin. In this study (Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (HbA1c) ≥7.5% and ≤11.0% (≥58 and ≤97 mmol/mol) with metformin ≥1500 mg/d (n = 1233) were randomized to ertugliflozin 5 (E5) or 15 (E15) mg/d, sitagliptin 100 mg/d (S100) or to co-administration of E5/S100 or E15/S100

EvidenceUpdates2018

165. Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial

Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial 29272062 2018 01 23 1463-1326 2017 Dec 22 Diabetes, obesity & metabolism Diabetes Obes Metab Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial. 10.1111/dom.13196 To determine the effects of early (...) intensive glycaemic control with intensive insulin treatment (IIT) or initial combined oral antidiabetic drug (COAD) therapy on long-term glycaemic control and the preservation of β-cell function in people with type 2 diabetes mellitus (T2DM). Newly diagnosed drug-naïve patients with T2DM from 8 outpatient diabetes centres were randomized to receive either IIT (n = 50; glargine/glulisine) or COAD (n = 47; glimepiride/metformin) as intensive treatment until the termination criteria to ensure euglycaemia

EvidenceUpdates2018

166. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease 28904068 2018 02 07 1524-4539 137 2 2018 Jan 09 Circulation Circulation Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. 119-129 10.1161/CIRCULATIONAHA.117.028268 Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity (...) and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes mellitus, established

EvidenceUpdates2018

167. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial 29227571 2018 01 23 1463-1326 2017 Dec 11 Diabetes, obesity & metabolism Diabetes Obes Metab Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients (...) : Analysis of results from the CONSENT trial. 10.1111/dom.13190 Metformin treatment for type 2 diabetes mellitus (T2DM) can be limited by gastrointestinal (GI) adverse events (AEs), resulting in treatment discontinuation. We investigated whether once-daily metformin extended release (XR) is superior in terms of GI tolerability, with non-inferior efficacy, compared with thrice-daily metformin immediate release (IR) in treatment-naïve Chinese patients with T2DM. This prospective, open-label, randomized

EvidenceUpdates2018

168. Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews

Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Roux-en-Y gastric bypass is a surgery that reduces the capacity of the stomach and the length of the small intestine through which food travels. Sleeve gastrectomy

Health Technology Assessment (HTA) Database.2018

169. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca Français Français CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary (...) There are two major categories of diabetes. Type 1 diabetes (T1D) is characterized by severe impairment or an absolute deficiency of insulin due to autoimmune destruction of pancreatic cells. Type 2 diabetes (T2D) is characterized by a combination of insulin resistance and decreased insulin secretion. Insulin is the mainstay of treatment for T1D. However, it may be difficult for some patients to reach target glycated hemoglobin (A1C) levels on insulin monotherapy. In some cases, hypoglycemia, excessive

CADTH - Issues in Emerging Health Technologies2018

170. Self-regulation resources and physical activity participation among adults with type 2 diabetes

Self-regulation resources and physical activity participation among adults with type 2 diabetes SAGE Journals: Your gateway to world-class journal research MENU Sign In Institution Society Access Options You can be signed in via any or all of the methods shown below at the same time. My Profile Sign in here to access free tools such as favourites and alerts, or to access personal subscriptions Email (required) Password (required) Remember me I don't have a profile I am signed in as: With my

Health psychology open2018 Full Text: Link to full Text with Trip Pro

171. Incidence of type 1 diabetes in China, 2010-13: population based study.

Incidence of type 1 diabetes in China, 2010-13: population based study. OBJECTIVE: To estimate the incidence of type 1 diabetes in all age groups in China during 2010-13. DESIGN: Population based, registry study using data from multiple independent sources. SETTING: National registration system in all 505 hospitals providing diabetes care, and communities of patients with diabetes in 13 areas across China, covering more than 133 million person years at risk, approximately 10% of the whole (...) population. PARTICIPANTS: 5018 people of all ages with newly diagnosed type 1 diabetes and resident in the study areas from 1 January 2010 to 31 December 2013. MAIN OUTCOME MEASURES: Incidence of type 1 diabetes per 100 000 person years by age, sex, and study area. Type 1 diabetes was doctor diagnosed and further validated by onsite follow-up. Completeness of case ascertainment was assessed using the capture mark recapture method. RESULTS: 5018 cases of newly diagnosed type 1 diabetes were ascertained

BMJ2018

172. Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial.

treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; P = .46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, -0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). Conclusions and Relevance: Among infants at risk for type 1 diabetes (...) Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial. Importance: Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. Objective: To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. Design

JAMA2018

173. Type 1 diabetes

there may be no evidence of autoimmune destruction of pancreatic beta cells; this is called idiopathic type 1 diabetes. History and exam presence of risk factors polyuria polydipsia young age weight loss blurred vision nausea and vomiting abdominal pain tachypnoea lethargy coma genetic predisposition geographic region infectious agents dietary factors Diagnostic investigations random plasma glucose fasting plasma glucose 2-hour plasma glucose plasma or urine ketones A1C (glycosylated haemoglobin (...) Type 1 diabetes Type 1 diabetes - Symptoms, diagnosis and treatment | BMJ Best Practice   Search  Type 1 diabetes Last reviewed: August 2018 Last updated: March 2018 Summary Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. Patients most often present with a few days or weeks of polyuria, polydipsia, weight loss, and weakness. Some patients may present with diabetic ketoacidosis. Intensive glycaemic control has been shown

BMJ Best Practice2018

174. Type 2 diabetes in adults

Type 2 diabetes in adults Type 2 diabetes in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Type 2 diabetes in adults Last reviewed: August 2018 Last updated: July 2018 Summary The cornerstone of therapy for all patients with diabetes is a personalised self-management programme, usually developed with the patient by a diabetes education nurse or nutritionist. Lifestyle changes plus metformin are initial (...) antihyperglycaemic therapy for most patients. Glycaemic goals and treatment choices are individualised. Blood pressure control, lipid management, smoking cessation, and glycaemic management reduce the risk of macrovascular complications such as heart attack and stroke. Glycaemic control and blood pressure management reduce the risk of microvascular complications (neuropathy, nephropathy, retinopathy). Selected glucose-lowering drugs reduce all-cause and cardiovascular mortality. Definition Type 2 diabetes

BMJ Best Practice2018

175. Type 2 diabetes in children

Type 2 diabetes in children Type 2 diabetes in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Type 2 diabetes in children Last reviewed: August 2018 Last updated: March 2018 Summary A progressive disorder due to a deficit in both insulin secretion and insulin action, with obesity being the primary cause in children. Often asymptomatic and diagnosed by screening in a high-risk individual (e.g., family (...) ). Treatment includes lifestyle modifications, metformin, and insulin. Definition Type 2 diabetes mellitus is a progressive disorder due to a deficit in both insulin secretion and insulin action leading to abnormal glucose metabolism and related metabolic derangements. Diagnosis is based on a fasting plasma glucose of 7 mmol/L or greater (126 mg/dL or greater) on 2 separate occasions, a random plasma glucose of 11.1 mmol/L or greater (200 mg/dL or greater) with symptoms of polyuria or polydipsia, a plasma

BMJ Best Practice2018

176. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-Term Randomized Controlled Trial in Adolescents With Type 1 Diabetes

Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-Term Randomized Controlled Trial in Adolescents With Type 1 Diabetes 29191844 2017 12 01 1935-5548 2017 Nov 30 Diabetes care Diabetes Care Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-Term Randomized Controlled Trial in Adolescents With Type 1 Diabetes. dc171604 10.2337/dc17-1604 Short-term studies with automated systems that suspend basal insulin when hypoglycemia is (...) predicted have shown a reduction in hypoglycemia; however, efficacy and safety have not been established in long-term trials. We conducted a 6-month, multicenter, randomized controlled trial in children and adolescents with type 1 diabetes using the Medtronic MiniMed 640G pump with Suspend before low (predictive low-glucose management [PLGM]) compared with sensor-augmented pump therapy (SAPT) alone. The primary outcome was percentage time in hypoglycemia with sensor glucose (SG) <3.5 mmol/L (63 mg/dL

EvidenceUpdates2018

177. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial 29246950 2017 12 16 1935-5548 2017 Dec 15 Diabetes care Diabetes Care Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. dc170417 10.2337/dc17-0417 To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c (...) . with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER

EvidenceUpdates2018

178. Effectiveness of a patient-centred, empowerment-based intervention programme among patients with poorly controlled type 2 diabetes: A randomised controlled trial

Effectiveness of a patient-centred, empowerment-based intervention programme among patients with poorly controlled type 2 diabetes: A randomised controlled trial 29149618 2017 11 17 1873-491X 79 2017 Nov 03 International journal of nursing studies Int J Nurs Stud Effectiveness of a patient-centred, empowerment-based intervention programme among patients with poorly controlled type 2 diabetes: A randomised controlled trial. 43-51 S0020-7489(17)30253-5 10.1016/j.ijnurstu.2017.10.021 Despite (...) extensive efforts and advances in evidence-based diabetes management, poor glycaemic control still remains a challenge in many countries. There is a paucity of research addressing the needs of patients with poorly controlled type 2 diabetes, or exploring the effectiveness of empowerment-based interventions in this vulnerable population. To evaluate the effectiveness of a patient-centred, empowerment-based programme on glycaemic control and self-management behaviours among patients with poorly controlled

EvidenceUpdates2018

179. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis of randomised controlled trials

Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis of randomised controlled trials 29193572 2018 01 10 1463-1326 2017 Nov 30 Diabetes, obesity & metabolism Diabetes Obes Metab Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. 10.1111/dom.13177 To perform a meta-analysis of randomized controlled trials (RCTs), including 6 recently published large-scale (...) cardiovascular outcome trials (CVOTs), to evaluate the risk of pancreatic cancer with incretin-based therapies in patients with type 2 diabetes (T2DM). For the period January 1, 2007 to May 1, 2017, the PubMed, Embase, Cochrane Central Register and ClininalTrials.gov databases were searched for RCTs in people with T2DM that compared incretin drugs with placebo or other antidiabetic drugs, with treatment and follow-up durations of ≥52 weeks. Two reviewers screened the studies, extracted the data and assessed

EvidenceUpdates2018

180. Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S

Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S 29269511 2017 12 22 1935-5548 2017 Dec 21 Diabetes care Diabetes Care Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S. dc172002 10.2337/dc17-2002 We sought to validate risk equations for complications of type 2 diabetes (RECODe) among (...) diverse populations. We compared risk predictions from RECODe equations and from two alternative risk models (UK Prospective Diabetes Study Outcomes Model 2 and ACC/AHA Pooled Cohort Equations) to observed outcomes in two studies: the Multi-ethnic Study of Atherosclerosis (MESA, n = 1,555 adults with type 2 diabetes, median follow-up 9.1 years) and the Jackson Heart Study (JHS, n = 1,746 adults with type 2 diabetes, median follow-up 8.0 years). Outcomes included nephropathy by multiple measures

EvidenceUpdates2018